Amplia Therapeutics Quarterly Activities and Cash Flow Reports Q1 2024

Report Highlights:

• Amplia was pleased to initiate Phase 2a of its ACCENT clinical trial, which aims to explore the safety, tolerability and efficacy of its best-in-class FAK inhibitor narmafotinib combined with chemotherapy drugs gemcitabine and Abraxane®.
• First patient dosing in January 2024, with South Korean sites for the ACCENT trial now recruiting patients. Investigational New Drug (IND) application cleared by US FDA for a trial of narmafotinib in the USA.
• Entitlement offer announced to fund Amplia through to Interim Anaylsis of ACCENT’s Phase 2a. The trial seeks to treat first-line patients with advanced pancreatic cancer.